The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR is well positioned, with CASGEVY gaining momentum, and multiple programs with encouraging data demonstrating the transformative potential of CTX310 for patients suffering from severe cardiovascular disease, as well as zugo-cel in oncology and autoimmune diseases.
Cyborg Score Rationale
The company enters 2026 with approximately $2 billion in cash, cash equivalents, and marketable securities and reported CASGEVY revenue exceeding $100M in 2025. However, the company faces significant profitability challenges with substantial operating losses, though a robust early-stage pipeline and strong analyst sentiment provide upside potential.
Top Insights
CASGEVY revenue exceeded $100M in 2025 with a nearly three-fold increase in patient initiations versus 2024
The company added a siRNA pillar through partnership with Sirius and is advancing lead siRNA asset CTX611 targeting Factor XI through the clinic
CTX320 targeting LPA demonstrated reductions of up to 73% in dose escalation; CTX321 incorporates updated guide RNA with approximately two-fold greater potency in preclinical testing
The company displays strong financial position with a low debt-to-equity ratio of 0.11 and high liquidity ratios including a current and quick ratio of 13.3
Named Competitors
Casgevy — FDA-approved CRISPR gene therapy for sickle cell and beta-thalassemia
CTX310 — In vivo gene editing for severe cardiovascular disease
Zugo-cel — CAR-T cell therapy for oncology and autoimmune indications
Editas Medicine — CRISPR-based gene editing company in clinical development
Recent Developments
(February 2026) Analysts raise price targets to $74-$82; stock trending up 8% amid positive clinical momentum
(January 2026) Company provides 2026 strategic roadmap with emphasis on CASGEVY launch acceleration and CTX310 cardiovascular program updates expected in H2
(January 2026) CASGEVY exceeded $100M revenue in 2025 with three-fold increase in patient initiations; enters 2026 with ~$2B cash
Open the full interactive CRISPR Therapeutics AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.